4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-25-001007
CHIEF FINANCIAL OFFICER sold 1,000 shares at $25.04 ($25,039)
- CHIEF FINANCIAL OFFICER acquired 14,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-12-13 | Option exercise 10b5-1 | +13,000 | $2.48 | $32,240 | 13,000 | D |
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2025-01-03 | Option exercise 10b5-1 | +1,000 | $2.48 | $2,480 | 14,000 | D |
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2025-01-03 | Sale 10b5-1 | −1,000 | $25.04 | $25,039 | 13,000 | D |
| Derivatives | |||||||
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-12-13 | Option exercise · Stock Option (right to buy) 10b5-1 | −13,000 | 155,556 | D | ||
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2025-01-03 | Option exercise · Stock Option (right to buy) 10b5-1 | −1,000 | 150,306 | D | ||
| Open-market sales · 1,000 sh · avg $25.04 · $25,039 | |||||||
Loading xslF345X05/form4-01072025_090141.xml…